Clinical Study
Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke
Table 1
Baseline characteristics.
| | Enoxaparin | Warfarin | | | () | () |
| Male sex | 18 (62.1%) | 24 (48.0%) | 0.227 | Age, years | 64 (53–67) | 66 (60–72) | 0.099 | Vascular risk factors | | | | Hypertension | 6 (20.7%) | 21 (42.0%) | 0.054 | Diabetes | 7 (24.1%) | 10 (20.0%) | 0.666 | Hyperlipidemia | 1 (3.4%) | 6 (12.0%) | 0.252 | Current smoker | 7 (24.1%) | 10 (20.0%) | 0.666 | Coronary artery disease | 1 (3.4%) | 1 (2.0%) | >0.999 | Laboratory findings on admission | | | | Platelet, ×103/μL | 149 (89–249) | 151 (108–229) | 0.955 | D-dimer, μg/mL | 15.08 (4.34–37.32) | 11.35 (2.84–37.25) | 0.413 | Fibrinogen, mg/dL | 377 (294–500) | 275 (184–432) | 0.062 | patterns | | | 0.612 | Single vascular territory | 5 (17.2%) | 11 (22.0%) | | Single lesion | 2 | 4 | | Multiple lesions | 3 | 7 | | Multiple vascular territories | 24 (82.8%) | 39 (78.0%) | | Prestroke medication | | | | Antiplatelet agents | 1 (3.4%) | 8 (16.0%) | 0.143 | Anticoagulants | 2 (6.9%) | 4 (8.0%) | >0.999 |
| Cancer profiles | | | | Primary cancer type | | | 0.229 | Lung | 11 (37.9%) | 27 (54.0%) | | Gastrointestinal | 6 (20.7%) | 6 (12.0%) | | Hepatobiliary | 5 (17.2%) | 10 (20.0%) | | Breast-gynecologic | 5 (17.2%) | 2 (4.0%) | | Other | 2 (6.9%) | 5 (10.0%) | | Systemic metastasis | 27 (93.1%) | 31 (62.0%) | 0.003 | Adenocarcinoma | 19 (65.5%) | 35 (71.4%) | 0.585 |
|
|
DWI: diffusion-weighted imaging.
|